medicalxpress.com
A breakthrough in non-invasive testing promises to revolutionize the diagnosis of endometriosis, a chronic condition affecting millions of women worldwide. Australian researchers have developed a blood test that detects early-stage endometriosis, potentially transforming patient care.
This development is significant as it offers a non-invasive, quicker, and potentially more cost-effective alternative to current diagnostic methods, ultimately aiming to improve women's health outcomes.
Australian researchers, through Proteomics International and collaboration with leading medical institutions, have developed a blood test promising to diagnose endometriosis non-invasively. Identifying 10 plasma protein biomarkers, the PromarkerEndo test could significantly expedite diagnosis, which currently takes an average of seven years, and reduce costs associated with invasive procedures like laparoscopies. Early detection, as highlighted in the study, can vastly improve treatment options and outcomes for affected women.
Diagnosis of endometriosis is often delayed, impacting many women's quality of life and fertility.
Current diagnostic methods for endometriosis are invasive and often lead to significant delays in diagnosis.
On average, it takes seven years to diagnose endometriosis, during which time symptoms worsen and fertility declines.
Endometriosis affects approximately 190 million women and teenagers worldwide, with significant symptoms such as severe pelvic pain and infertility. Diagnosis typically involves invasive procedures like laparoscopies, which not only delay confirmation by years but also contribute to deteriorating quality of life and loss of fertility throughout the wait.
"Currently, it takes on average seven years for a woman to receive a diagnosis," noted Professor Peter Rogers from the University of Melbourne.
Identifying protein biomarkers enables early disease detection and potentially transforms clinical practice.
Biomarker-based blood tests offer a promising non-invasive alternative for early detection of endometriosis.
The identification of specific biomarkers in blood could revolutionize the speed and accuracy of diagnoses.
The development of the PromarkerEndo, a blood test identifying 10 specific protein biomarkers associated with endometriosis, represents a major advancement. This test aims to distinguish between healthy individuals and those with symptomatic or early-stage endometriosis, circumventing the need for more invasive methods.
Dr. Richard Lipscombe stated, "We identified 10 protein biomarkers, or 'fingerprints' in the blood, that can be found using our test in women and girls with endometriosis."
Early detection can broaden treatment options and enhance patient outcomes in endometriosis care.
Early diagnosis expands therapeutic opportunities and improves response to treatments.
Access to early diagnosis and treatment allows for more effective management of symptoms and disease progression.
Endometriosis not only causes significant discomfort but also poses challenges to fertility and overall health. By providing early diagnosis, the PromarkerEndo test could allow earlier and more effective treatment interventions, potentially improving the response to therapies like laser ablation.
"Detecting endometriosis at an early stage increases treatment options and may improve a patient’s response to laser ablation or the medical therapies currently used," said Professor Rogers.
ACOG 2021: What Can We Look Forward to?
ACOG 2021: What Can We Look Forward to?
